Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and Competitive analysis by DelveInsight| Companies – Selecta Biosciences, Arthrosi Therapeutics, AstraZeneca, Fuji Yakuhin

July 20 23:58 2022
Gout Market Size, Epidemiology, Treatment, Therapies, Pipeline and Competitive analysis by DelveInsight| Companies - Selecta Biosciences, Arthrosi Therapeutics, AstraZeneca, Fuji Yakuhin
Gout Market

Gout is a common form of inflammatory arthritis. It’s due to a crystal called uric acid. Gout causes pain and swelling in one or more joints. It typically affects the big toe. But it’s also found in other joints, including the knee, ankle, foot, hand, wrist and elbow. It is more common in men than in women. Gout usually develops in middle age.


DelveInsight’s “Gout Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Gout, historical and forecasted epidemiology as well as the Gout market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


To know more about the Gout Market Report, click here: Gout Market Assessment


Some facts of Gout Market are:

  • In a study based on US National Health and Nutrition Examination Survey [NHANES] (n.d.), conducted in 2007–2008, 3.9% of the US population reported physician-diagnosed prevalent gout. The male to female ratio was 3:1.
  • Roddy et al. (2020) quoted that prevalence of gout vary widely according to the population studied and methods employed but range from a prevalence of <1% to 6.8%.
  • In the UK, based on the Clinical Practice Research Data link (CPRD) (2012), the prevalence of gout was 2.49% (95% CI, 2.48−2.51%) in 2012.
  • The prevalence of Gout is higher in men than in women. Men can be three times more likely than women to get it because they have higher levels of uric acid most of their lives. Women reach these uric acid levels after menopause.
  • According to the study conducted by Bonnemaire et al. (2008), the prevalence of gout in Germany was reported to be 1.4% in the general population in 2000–2005, which was the same prevalence as in the UK in that period, determined using the same case definition and data source. In comparison, France and Italy have a lower prevalence of gout.
  • SEL-212, AR882 and other emerging therapies are giving positive topline results, in their clinical trials. These emerging therapies are in mid phase of its clinical trials and are awaiting a launch which will make the pipeline for Gout robust.


To get detailed analysis of the Gout Market and Epidemiology facts, click here: Gout Market Analysis


Scope of Gout Market Report:

  • The report covers the descriptive overview of Gout, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Gout epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Gout are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Gout market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Gout market


Get the complete scope of the Gout Market: Gout Market Report


Some of the Gout Companies in the market

  • Selecta Biosciences
  • Arthrosi Therapeutics
  • AstraZeneca
  • Fuji Yakuhin
  • And Others


Get access to free sample report, here: Gout Market Companies


Gout Pipeline Therapies are:

  • SEL-212
  • AR882
  • Dotinurad (URECE)
  • ZURAMPIC (lesinurad)
  • And Others


To know more in detail about the Gout Companies and Pipeline Therapies, click here: Gout Pipeline Therapies and Drugs


Table of Contents:

1. Key Insights

2. Executive Summary of Gout

3. Competitive Intelligence Analysis for Gout

4. Gout: Market Overview at a Glance

5. Gout: Disease Background and Overview

6. Patient Journey

7. Gout Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Gout Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Gout: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Gout

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


About Delveinsight:

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/gout-market